ArticleJournal of thoracic disease2025
SH3BGRL2 as a vital tumor suppressor and prognostic factor in human esophageal squamous cell carcinoma.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal squamous cell carcinoma (ESCC), a highly aggressive malignancy associated with dismal prognosis, is a global healthcare threat. The molecular mechanisms underlying the carcinogenesis and progression of ESCC remain to be elucidated. This study aims to systematically dissect the pivotal genes and molecular mechanisms that orchestrate the progression of ESCC. Methods: RNA-sequencing was performed to identify differentially expressed genes between resected ESCC tumor samples and paired adjacent normal tissues. The protein expression levels of SH3 domain binding glutamate rich protein-like 2 (SH3BGRL2) were assessed via immunohistochemistry (IHC) staining in a tissue microarray of 247 cases of ESCC tumor samples and paired normal tissues. Subsequent Results: RNA-sequencing and IHC analyses both revealed significant downregulation of SH3BGRL2 in ESCC tissues (P<0.01). Patients with higher SH3BGRL2 expression exhibited significantly longer disease-free survival (DFS) and overall survival (OS) (DFS: 47.1 Conclusions: SH3BGRL2 acts as a key tumor suppressor and prognostic determinant in ESCC, which represents a novel insight into the pathogenesis of this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.